<div id="readability-page-1"><p>In a report released on May 12, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals, with a price target of <span id="expert-recommendation-target">$51.00</span>. The company’s shares closed yesterday at $11.43.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Abrahams is a 5-star analyst with an average return of <span>10.1%</span> and a 51.10% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, BioCryst, and ACADIA Pharmaceuticals.</p> <p>Currently, the analyst consensus on Corbus Pharmaceuticals is a Strong Buy with an average price target of $40.78, which is a 256.78% upside from current levels. In a report released yesterday, Oppenheimer also reiterated a Buy rating on the stock with a $54.00 price target.</p></div>

CRBP

IBBQ

LABU

SBIO

<p>RBC Capital has reaffirmed a Buy rating on Corbus Pharmaceuticals (CRBP) with a price target of $51.00, while the shares closed at $11.43. Analyst Brian Abrahams, a 5-star analyst, has an average return of 10.1% and a 51.10% success rate. The consensus on Corbus is a Strong Buy with an average price target of $40.78, indicating a potential upside of 256.78%. Oppenheimer also reiterated a Buy rating with a $54.00 price target.</p>

Tip Ranks

Corbus Pharma

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

ALPS Medical Breakthrough

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

ROYAL BANK OF CANADA

Gilead Sciences

BioCryst Pharma

Acadia Pharma

Oppenheimer

RBC Capital Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)